Provided by Tiger Trade Technology Pte. Ltd.

Amneal Pharmaceuticals, Inc.

13.47
-0.1100-0.81%
Volume:325.73K
Turnover:4.36M
Market Cap:4.23B
PE:837.11
High:13.58
Open:13.50
Low:13.30
Close:13.58
52wk High:13.75
52wk Low:6.69
Shares:314.36M
Float Shares:168.50M
Volume Ratio:0.26
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0161
EPS(LYR):-0.3783
ROE:-881.26%
ROA:6.79%
PB:-38.69
PE(LYR):-35.61

Loading ...

Assessing Amneal Pharmaceuticals (AMRX) Valuation After Recent Share Price Momentum

Simply Wall St.
·
Jan 22

Amneal Pharma: Expects to Meet or Exceed Its 2025 Full-Year Financial Guidance

THOMSON REUTERS
·
Jan 13

Amneal Pharmaceuticals Inc FY2025 Shr View $0.80, REV View $3.01 Bln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 13

Amneal Pharmaceuticals Expects to Meet or Exceed 2025 Financial Guidance

Reuters
·
Jan 13

Amneal Pharmaceuticals Announces Plans to Launch Accessibility Index and Expand Efforts to Improve Medicine Affordability, Availability, Innovation, and Knowledge

Reuters
·
Jan 13

BRIEF-KeifeRX Announces Research Collaboration & Option Agreement With Amneal Pharmaceuticals

Reuters
·
Jan 10

Keiferx: Financial Terms of Agreement Were Not Disclosed

THOMSON REUTERS
·
Jan 10

Keiferx Announces Research Collaboration and Option Agreement With Amneal Pharmaceuticals to Advance Kfrx06, a Brain-Penetrant Lrrk2 Program for Parkinson’s Disease

THOMSON REUTERS
·
Jan 10

Amneal Pharmaceuticals Partners with KeifeRx to Advance LRRK2 Inhibitor for Parkinson’s Disease

Reuters
·
Jan 10

Truist Securities Adjusts Price Target on Amneal Pharmaceuticals to $15 From $14, Maintains Buy Rating

MT Newswires Live
·
Jan 07

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and Xgeva®

THOMSON REUTERS
·
Dec 23, 2025

Amneal Pharma - Expects to Commercialize Six Biosimilars by 2027

THOMSON REUTERS
·
Dec 23, 2025

FDA Approves Amneal and mAbxience Denosumab Biosimilars

Reuters
·
Dec 23, 2025

Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection

Simply Wall St.
·
Dec 21, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following FDA Green Light For Hospital Epinephrine

Simply Wall St.
·
Dec 19, 2025

The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following Key FDA Wins For Epinephrine And Complex Generics

Simply Wall St.
·
Dec 11, 2025

FDA Approves Amneal Epinephrine Injection for U.S. Hospitals

Reuters
·
Dec 10, 2025

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

THOMSON REUTERS
·
Dec 10, 2025

Amneal Pharmaceuticals Initiated at Overweight by Barclays

Dow Jones
·
Dec 09, 2025

U.S. RESEARCH ROUNDUP-AstraZeneca, Confluent, Pepsico

Reuters
·
Dec 09, 2025